Showing 1 - 10 of 10,154
In the late 1980s, the Prospective Payment System and the expansion of managed care plans forced hospitals to be cost efficient. The increased number of hospital mergers suggests that merging is a way to become more efficient to ensure long-run survival. This study presents an economic framework...
Persistent link: https://www.econbiz.de/10005770012
In this paper, we argue that lower prices for pharmaceuticals can be achieved by fostering a new type of competition in the pharmaceutical industry. Lower drug development costs, and hence prices, can be brought about by abolishing national drug administrations and replacing them with private...
Persistent link: https://www.econbiz.de/10012752308
Cross-country variability in regulatory frameworks, industrial policy, physician/pharmacy autonomy, brand/generic distinctions, and in the practice of medicine contributes to ambiguous interpretations of pharmaceutical cost comparisons. Here we report cross-country comparisons that: (i) focus on...
Persistent link: https://www.econbiz.de/10010852302
Although learning-by-doing is believed to be an important source of productivity growth, there is limited evidence that production volume affects productivity in a causal sense. We document evidence of learning-by-doing in a highly skilled profession where stakes are high; advanced cancer...
Persistent link: https://www.econbiz.de/10010884321
Although learning-by-doing is believed to be an important source of productivity growth, there is limited evidence that production volume affects productivity in a causal sense. We document evidence of learning-by-doing in a highly skilled profession where stakes are high; advanced cancer...
Persistent link: https://www.econbiz.de/10010945096
We examine the impact of loss of U.S. patent exclusivity (LOE) on the prices and utilization of specialty drugs between 2001 and 2007. We limit our empirical cohort to drugs commonly used to treat cancer and base our analyses on nationally representative data from IMS Health. We begin by...
Persistent link: https://www.econbiz.de/10010950850
Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to steer drug demand and to control expenses. For example, they introduce reference pricing or tiered co-payments to enhance drug substitution and competition. Since 2006, Germany...
Persistent link: https://www.econbiz.de/10010956760
General Practitioners (GP) have limited means to compete. As quality is hard to observe by patients, GPs have incentives to signal quality by using instruments patients perceive as quality.
Persistent link: https://www.econbiz.de/10011263928
Taking evolutionary view of markets, Harold Demsetz hypothesized that firms differ persistently in efficiency and that industry concentration results from growth of efficient firms at the expense of inefficient ones. We test the hypothesis with high quality microdata from the US hospital...
Persistent link: https://www.econbiz.de/10005245482
entry and exit behavior. We develop theoretical predictions based on the model of Lakdawalla and Philipson, in which for … be quicker to enter and exit than not-for-profits in response to changing market conditions. We test this hypothesis … using data for all U.S. hospitals from 1984 through 2000. Examining annual and regional entry and exit rates, for …
Persistent link: https://www.econbiz.de/10005085246